Introduction {#sec1}
============

Esophagogastroduodenoscopy (EGD) is an invasive outpatient procedure that has been widely used for the diagnosis, treatment, screening, and follow-up of various upper gastrointestinal diseases \[[@cit0001]--[@cit0004]\]. Application of sedation and analgesia during the procedure provides increased tolerance, comfort, and satisfaction by decreasing the gag reflex, dizziness, and vomiting, and improves the efficiency of the procedure \[[@cit0005]--[@cit0007]\].

Midazolam is a short-acting, water-soluble benzodiazepine that inhibits the central nervous system by binding to γ-aminobutyric acid type A (GABA~A~) receptors. It has anxiolytic, sedative-hypnotic, anticonvulsant, and antegrade amnestic properties \[[@cit0008]\]. The combination of opioid analgesic meperidine with midazolam is the most frequently used sedation regimen in gastrointestinal endoscopy worldwide \[[@cit0009]\]. Propofol (2,6-diisopropyl phenol) has faster sedation induction and shorter half-life compared to midazolam/meperidine, and its use has increased annually \[[@cit0007], [@cit0009]--[@cit0012]\]. In spite of its advantages, propofol has no analgesic effect. Moreover, propofol sedation may readily provide general anesthesia at higher doses and, contrary to midazolam and meperidine, it has no pharmacological antagonist \[[@cit0013]\].

Although many studies and meta-analyses on the effectiveness, sedation properties, and complications of propofol or midazolam/meperidine in upper gastrointestinal endoscopy (UGE) exist, prospective randomized studies comparing these two regimens are few \[[@cit0005], [@cit0009], [@cit0010]--[@cit0015]\].

Aim {#sec2}
===

We aimed to compare the sedation properties, cardiopulmonary side effects, risk factors, as well as patient and endoscopist satisfaction of propofol and midazolam/meperidine.

Material and methods {#sec3}
====================

Study design and patient selection {#sec3.1}
----------------------------------

This was a prospective, randomized, double-blind study to compare propofol and midazolam/meperidine sedation. The study was conducted in the Endoscopy Center of our hospital. The study protocol was approved by the local Hospital Ethics Committee, conducted according to the Declaration of Helsinki, and all patients provided written informed consent.

A hundred out of the 125 consecutive patients who underwent elective outpatient diagnostic UGE between February 2014 and June 2014 were included in the study. Exclusion criteria were: known sensitivity or allergy to study drugs, egg, and soybean oil; age \< 18 years; pregnant or breast-feeding; risk of difficult intubation (i.e., short-thick neck, inability to widely open the mouth, Mallampati class III--IV); history of obstructive sleep apnea syndrome; American Society of Anesthesiologists (ASA) physical classification status \> III; and history of complications in previous sedations.

All endoscopies were performed by the same general surgeon, who had more than 5 years of experience in gastrointestinal tract endoscopy and who was blinded to the aim of the study. The patients, endoscopy, and recovery room nurse were also unaware of the aim of the study. Patients were allocated to the propofol (group P) and meperidine/midazolam (group MM) groups by computer-generated simple randomization. All sedation protocols were performed by the same anesthesiologist who was also blinded to the aim of the study.

Sedation protocol {#sec3.2}
-----------------

All the patients received 0.9% sodium chloride at 10 ml/kg/h intravenously and 3 l/min oxygen via nasal cannula in the endoscopy unit. The pharynx of the patients was topically anesthetized with three puffs of lidocaine spray (Xylocaine pump spray 10%, AstraZeneca Inc., Turkey) before the procedure. In group P, sedation was performed with an initial bolus of 1 mg/kg propofol (propofol 2%, Fresenius Kabi, Istanbul, Turkey) intravenously followed by repeated doses of 10 to 20 mg propofol intravenously, as needed, for continuous sedation. In group MM, sedation was started with a bolus dose of 0.4 mg/kg meperidine (Aldolan, Liba Lab, Istanbul, Turkey) intravenously followed three minutes later by 0.05 mg/kg midazolam intravenously (Dormicum, Roche, Istanbul, Turkey), and sedation was maintained with repeated intravenous doses of 5 to 10 mg meperidine and 1 to 2 mg midazolam. The level of sedation was evaluated with the Observer's Assessment of Alertness/Sedation Scale (OAA/S), every one minute after the initial bolus injection of propofol or meperidine/midazolam ([Table I](#t0001){ref-type="table"}) \[[@cit0016]\]. A moderate sedation level was provided throughout the procedure (OAA/S 2--4). Flumazenil (Anexate, Deva, Istanbul, Turkey) and naloxone (Naloxone Hydrochloride, Abbott, Istanbul, Turkey), the antagonists of midazolam and meperidine, as well as all the equipment needed for resuscitation, were available in the endoscopy room.

###### 

Observer's assessment of alertness/sedation scale (OAA/S)

  Observation                                                   Score level
  ------------------------------------------------------------- -------------
  Responds readily to name spoken in normal tone                5
  Lethargic response to name spoken in normal tone              4
  Responds only after name is called loudly and/or repeatedly   3
  Responds only after mild prodding or shaking                  2
  Responds only after painful trapezius squeeze                 1
  Does not respond to painful trapezius squeeze                 0

Patient monitoring and data collection {#sec3.3}
--------------------------------------

In the endoscopy unit, electrocardiography (ECG), heart rate (HR), noninvasive blood pressure (NIBP), respiratory rate (RR), and peripheral oxygen saturation (SpO~2~) were monitored continuously in all the patients with a standard monitoring device (Draeger Infinity Delta, Draeger Medical Systems, Inc. Telford, PA, USA) before the application of topical anesthesia until discharge from the hospital. All monitoring parameters, duration of endoscopy, awake time (i.e., time for the patient to have an OAA/S score of 5 in the recovery room), time to hospital discharge after the endoscopy, cardiopulmonary side effects, and patient characteristics were recorded by the same research resident, who was unaware of the group assignment of each patient.

Cardiopulmonary side effects and treatment {#sec3.4}
------------------------------------------

The NIBP measurements were automatically performed every two minutes throughout the endoscopy; thereafter NIBP was measured every 5 min until hospital discharge. HR, RR, and SpO~2~ were evaluated continuously. Cardiopulmonary side effects included: 1) hypotension (i.e., more than 30% decrease in baseline mean arterial pressure (MAP) or systolic arterial pressure (SAP) \< 90 mm Hg), 2) bradycardia (HR \< 50 bpm), 3) hypoxemia (SpO~2~ \< 90% on oxygen supplementation), 4) apnea (arrest of respiration more than 15 s), 5) other causes (i.e., arrhythmia, chest pain, or pulmonary edema), and 6) permanent brain damage and death. An additional 250 ml isotonic saline solution was infused into patients who developed hypotension. Five mg of ephedrine was administered to patients whose hypotension was not corrected by ephedrine or whose systolic arterial pressure was \< 90 mm Hg. Bradycardia was treated with intravenous atropine 0.5 mg. If SpO~2~ \< 90% continued for more than 15 s, the chin lift maneuver was used. If SpO~2~ 90% did not rise above 90% in spite of the chin lift maneuver, assisted ventilation was applied and flumazenil and/or naloxone was injected.

Post-procedural follow-up and discharge evaluation {#sec3.5}
--------------------------------------------------

Following the endoscopy, the patients were transferred to the recovery room. The blood pressure, HR, and SpO~2~ values were measured and patient consciousness was evaluated by the same recovery room nurse who was also unaware of the patient's group assignment. Patients without hypotension (mean arterial pressure \< 70 mm Hg), bradycardia (HR \< 60 bpm), and hypoxemia (SpO~2~ \< 95% in room air), who could sit in bed without help, and who were fully conscious (OAA/S score 5) were determined to be ready for discharge from the hospital.

Evaluation of patient satisfaction {#sec3.6}
----------------------------------

The patients were asked by the recovery room nurse to evaluate the endoscopic procedure. They were asked to give a score for the pain, discomfort, or gag reflex that they experienced during the procedure (0 = none, 100 = severe) and the level of sedation satisfaction (0 = very dissatisfied, 100 = very satisfied) on a 100 mm visual analog scale (VAS). They were also asked if they remembered waking up (yes/no) during the procedure.

Evaluation of the endoscopist's satisfaction {#sec3.7}
--------------------------------------------

The endoscopist was asked to evaluate his or her satisfaction with sedation (0 = very dissatisfied, 100 = very satisfied) using the VAS.

Procedure-related times {#sec3.8}
-----------------------

Procedure-related times were defined were as follows: 1) endoscopy time (i.e., the time interval between the start of UGE and endoscope removal), 2) awake time (i.e., the time interval between endoscope removal and patient reaching an OAA/S score of 5), and 3) time to hospital discharge (i.e., the time interval between endoscope removal and hospital discharge).

Statistical analysis {#sec3.9}
--------------------

The SPSS software package for Windows (Statistical Package for Social Sciences, version 17.0, SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Quantitative variables including age, body mass index (BMI), procedure-related times, drug dose, as well as patient and endoscopist satisfaction, were expressed as mean ± standard deviation (SD). Categorical variables such as patient characteristics and adverse events were expressed as the number and percentage of patients. Quantitative variables were analyzed with the Kolmogorov-Smirnov test to assess the normality of the data distribution, and normally distributed variables were compared with Student's *t*-test. The χ^2^ or Fisher's exact test was used to compare categorical variables.

To calculate the sample size for this study, the incidence of adverse cardiopulmonary events including hypotension and hypoxemia was assumed to be approximately 34% for propofol sedation, as was found in a previous study \[[@cit0017]\]. Power analysis with α = 0.05 and β = 0.2 to determine a 50% reduction in adverse cardiopulmonary events with meperidine and midazolam revealed that each group required a minimum of 36 patients. A value of *p* \< 0.05 was taken to be statistically significant.

Results {#sec4}
=======

Patient characteristics {#sec4.1}
-----------------------

One hundred and twenty-five consecutive patients who underwent elective outpatient diagnostic UGIE were enrolled in the study. Twelve patients did not fulfill the inclusion criteria, 6 patients did not wish to participate, and 7 patients were lost to follow-up. Ultimately, 50 patients in both groups were analyzed ([Figure 1](#f0001){ref-type="fig"}).

![Flowchart of the study](WIITM-11-28080-g001){#f0001}

None of the patients developed endoscopy-related complications. The most frequent indication for UGIE was epigastric pain/discomfort (*n* = 62). Other indications were nausea and vomiting (*n* = 16), anemia (*n* = 7), dysphagia (*n* = 6), hematemesis (*n* = 5), and weight loss (*n* = 4). There were no significant differences between the groups in terms of age, gender, ASA classification, BMI, smoking/alcohol use, presence of comorbid diseases, or history of medical treatment and surgery. The mean total dose of propofol administered was 88.0 ±26.1 mg; the mean midazolam and meperidine doses were 3.61 ±0.91 mg and 28.92 ±5.96 mg, respectively ([Table II](#t0002){ref-type="table"}).

###### 

Characteristics of patients

  Characteristics             Propofol (*n* = 50)   M/M (*n* = 50)   *P*-value
  --------------------------- --------------------- ---------------- -----------
  Age \[years\]               47 ±17                41 ±15           0.052
  Gender, M/F                 23/27                 21/29            0.840
  BMI \[kg/cm^2^\]            27.0 ±4.8             26.6 ±5.3        0.681
  ASA classification:                                                0.256
   I                          35                    40               
   II                         13                    10               
   III                        2                     0                
  Tobacco/alcohol use         8                     10               0.374
  Co-existing disease:        18                    15               0.523
   Cardiovascular disorders   12                    8                
   Diabetes mellitus          2                     3                
   Others                     6                     8                
  Medical treatment:          18                    15               0.523
   Cardiovascular drugs       12                    8                
   Oral antidiabetics         2                     3                
   Others                     6                     8                
  Operation history:          19                    18               0.682
   Gastrointestinal surgery   5                     8                
   Others                     15                    11               
  Total drug dose \[mg\]:                                            
   Propofol                   88.0 ±26.1            --               
   Meperidine                 --                    28.92 ±5.96      
   Midazolam                  --                    3.61 ±0.91       

Data are given as mean ± SD or number and percent of cases. ASA -- American Society of Anesthesiologists, BMI -- body mass index, M/M: midazolam + meperidine.

Procedure-related times {#sec4.2}
-----------------------

The results of the comparisons of endoscopy time, awake time, and time to hospital discharge between the two groups are summarized in [Table III](#t0003){ref-type="table"}. There was no significant difference between the two groups in terms of endoscopy time (*p* = 0.145). We found that awake time and time to hospital discharge were significantly shorter with propofol compared to meperidine/midazolam (awake time: *p* = 0.030, time to hospital discharge: *p* = 0.019; [Table III](#t0003){ref-type="table"}).

###### 

Procedure-related times and adverse events

  Variable                             Propofol (*n* = 50)   M/M (*n* = 50)   *P*-value
  ------------------------------------ --------------------- ---------------- -----------
  Endoscopy time \[min\]               7.60 ±2.68            8.38 ±2.63       0.145
  Awake time \[min\]                   6.58 ±4.72            9.32 ±4.26       0.030
  Time to hospital discharge \[min\]   27.60 ±7.88           32.00 ±10.54     0.019
  Adverse events:                      10 (20)               2 (4)            0.025
   Hypoxemia                           7 (14)                2 (4)            0.160
   Apnea                               4 (8)                 1 (2)            0.362
   Hypotension                         6 (12)                0 (0)            0.027
   Bradycardia                         0 (0)                 0 (0)            \> 0.999
   Permanent damage or death           0 (0)                 0 (0)            \> 0.999

Data are presented as mean ± SD or number (%) of the patients. M/M -- midazolam + meperidine.

Adverse cardiopulmonary events {#sec4.3}
------------------------------

The incidence rates of adverse cardiopulmonary events are summarized in [Table III](#t0003){ref-type="table"}. We observed significantly more adverse cardiopulmonary events with propofol compared to meperidine/midazolam (20% vs. 4%, *p* = 0.025). Hypotension incidence was significantly higher in the propofol group compared to the meperidine/midazolam group (12% vs. 0%, *p* = 0.027). The difference between the groups with respect to hypoxemia incidence and apnea incidence was not statistically significant (*p* = 0.160 and *p* = 0.362, respectively). No patients showed permanent damage, death, or bradycardia.

Satisfaction {#sec4.4}
------------

Patient and endoscopist satisfaction for the two groups were compared, and their results are summarized in [Table IV](#t0004){ref-type="table"}. None of the patients remembered the UGIE procedure. Patients in group P experienced significantly less discomfort/pain and/or gagging compared to group MM (*p* \< 0.001). These results also showed higher patient and endoscopist satisfaction in group P (*p* = 0.007 and *p* \< 0.001, respectively).

###### 

Patient's and endoscopist's satisfaction

  Variable                                   Propofol (*n* = 50)   M/M (*n* = 50)   *P*-value
  ------------------------------------------ --------------------- ---------------- -----------
  Patient's discomfort/pain and/or gagging   8.3 ±3.7              11.4 ±5.4        \< 0.001
  Patient satisfaction                       92.5 ±5.1             89.2 ±6.7        0.007
  Recollection of the procedure (yes/no)     0/50                  0/50             1.000
  Endoscopist satisfaction                   85.2 ±4.6             79.7 ±5.9        \< 0.001

Data are presented as mean ± SD or number of patients. M/M -- midazolam + meperidine.

Discussion {#sec5}
==========

Esophagogastroduodenoscopy is an essential and widely accepted minimal invasive tool for diagnosing, treating, and screening upper gastrointestinal disorders \[[@cit0018], [@cit0019]\]. The use of sedation for EGD varies from country to country and even differs within the same country because of social, cultural, economic, and regulatory influences \[[@cit0020]\]. Although EGD can be safely carried out without sedation, nowadays the vast majority of EGDs in developed countries are performed while the patient is sedated \[[@cit0010], [@cit0021], [@cit0022]\].

The goal of sedation during EGD is to improve patient satisfaction by decreasing anxiety and embarrassment, relieve pain, and prevent recollection of the procedure. In spite of this, most of the adverse cardiopulmonary events during endoscopy are related to sedation \[[@cit0023]\]. The most common sedation regimen for EGD worldwide is propofol and midazolam with an opioid such as meperidine, and propofol use has been gaining in popularity because of increased endoscopist satisfaction compared to traditional sedation in recent years \[[@cit0010], [@cit0020], [@cit0022]\].

In this study, we found that midazolam/meperidine is superior to propofol with respect to the occurrence of adverse cardiopulmonary events, particularly hypotension. All of the patients who had hypotension were in the propofol group (12%), and this was a significant difference. Transient hypotension was sufficiently corrected by fluid loading, and there was no need for vasopressor treatment in any patients. Although hypoxemia and apnea were more frequently associated with propofol, no significant difference was detected between the groups ([Table III](#t0003){ref-type="table"}). The chin lift maneuver was necessary in 4 (8%) patients in group P and 1 (2%) patient in group MM to address apnea. Hypoxemia and apnea were quickly addressed with the chin lift maneuver and by increasing the rate of nasal oxygen flow, and there was no need for endotracheal intubation and mechanical ventilation or for flumazenil and/or naloxone injection.

Previous studies have reported that propofol and meperidine/midazolam have a similar cardiopulmonary safety profile. In a meta-analysis that included 12 randomized controlled studies, Qadeer *et al.* concluded that the risk of cardiopulmonary complications during EGD was similar in propofol sedation compared to midazolam \[[@cit0012]\]. In a recent meta-analysis of eight randomized controlled studies involving EGD (425 patients) that compared propofol sedation with midazolam, there was no difference in cardiopulmonary complications between propofol and midazolam \[[@cit0024]\]. A prospective randomized study by Vargo *et al.* \[[@cit0015]\] found no difference between propofol and meperidine/midazolam sedation with respect to adverse cardiopulmonary event incidence during advanced upper endoscopic procedures. Their observed incidence of hypotension in the propofol group (15.9%) was comparable to our findings, but it was much higher in the meperidine/midazolam group (18.9%) compared to our findings. The percentage of other adverse events such as hypoxemia and apnea that we observed was lower than the percentages reported by Vargo *et al.* \[[@cit0015]\], due to the larger doses of propofol and meperidine/midazolam used in their study. Moreover, another study found that propofol sedation does not increase the risk of hypotension compared to midazolam sedation, even in patients with cirrhosis \[[@cit0025]\].

Contrary to the studies mentioned above, a closed claim analysis in the USA found that propofol has a higher incidence of cardiorespiratory complications than non-propofol-based sedation during endoscopy \[[@cit0026]\]. Gangi *et al.* \[[@cit0027]\] stated that propofol is an independent risk factor for adverse cardiovascular events in endoscopic procedures of the digestive system. In a retrospective analysis, Goudra *et al.* \[[@cit0028]\] found that the number of cardiac arrests during EGD with propofol sedation was 14 in 12,166 patients and in non-propofol-based sedation was zero in 15,108 patients, and that cardiac arrests were primarily related to airway problems that resulted in hypoxemia.

Procedure-related times were compared between the groups, and the results of the present study demonstrate that awake time and time to hospital discharge were significantly shorter for propofol sedation compared to meperidine/midazolam sedation. These findings are comparable to those of other studies \[[@cit0015], [@cit0024], [@cit0025], [@cit0029], [@cit0030]\]. In a recent meta-analysis, propofol sedation was shown to reduce recovery time and discharge time compared to midazolam with or without meperidine, and no significant difference in amnesia was detected between the two sedation regimens after EGD \[[@cit0024]\]. Propofol seems to be more favorable compared to meperidine/midazolam for short procedures such as EGD, in terms of faster recovery and earlier discharge.

We found that propofol had better patient and endoscopist satisfaction and no patients reported recollection of the procedure. These results align with a number of previous studies \[[@cit0010], [@cit0022], [@cit0029], [@cit0031]\]. In contrast, three recent meta-analyses reported no differences in patient and endoscopist satisfaction between propofol and meperidine/midazolam sedation for endoscopic procedures \[[@cit0024], [@cit0032], [@cit0033]\]. This difference may be related to medication dose, patient characteristics (e.g., age, gender), sedation level, and the low sample size of the studies.

Conclusions {#sec6}
===========

The results obtained in this study revealed that propofol sedation has a faster recovery time and earlier discharge after EGD, as compared to meperidine/midazolam sedation. Although a high satisfaction level was observed with both sedation regimens, patient and endoscopist satisfaction was significantly greater for propofol sedation. Compared with meperidine/midazolam, adverse cardiopulmonary events seem to be higher with propofol. Complications can be prevented with strict monitoring of peripheral oxygen saturation, HR, blood pressure, electrocardiography, and oxygen supplementation. Propofol may be preferable for short procedures such as EGD, but it should be used carefully with trained staff.
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